- 专利标题: UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION
-
申请号: US17631886申请日: 2020-07-27
-
公开(公告)号: US20220387395A1公开(公告)日: 2022-12-08
- 发明人: Arthur T. SANDS , Neil F. BENCE , Christoph W. ZAPF , Frederick COHEN , Chenbo WANG , Thomas CUMMINS , Hiroko TANAKA , Morgan LAWRENZ , Mario CARDOZO , Dahlia WEISS , Jennifa GOSLING
- 申请人: Nurix Therapeutics, Inc.
- 申请人地址: US CA San Francisco
- 专利权人: Nurix Therapeutics, Inc.
- 当前专利权人: Nurix Therapeutics, Inc.
- 当前专利权人地址: US CA San Francisco
- 国际申请: PCT/US2020/043788 WO 20200727
- 主分类号: A61K31/4196
- IPC分类号: A61K31/4196 ; C07D249/10 ; C07D249/08 ; C07D405/06 ; C07D498/20 ; C07D401/12 ; C07D403/12 ; C07D471/04 ; C07D498/04 ; C07D401/14 ; C07D471/20 ; C07D487/04 ; C07D405/14 ; C07D413/12 ; C07D413/14 ; C07D471/10 ; C07D491/107 ; C07D487/10 ; C07D498/10 ; C07D417/12 ; C07F5/02 ; A61K38/17 ; A61K35/17 ; A61K39/395 ; A61K31/704 ; A61K31/427 ; A61K31/407 ; A61K38/14 ; A61K31/473 ; A61K31/7048 ; A61K31/136 ; A61K31/351 ; A61K38/12 ; A61K31/4995 ; A61K31/337 ; A61K38/08 ; A61K31/437 ; A61K31/439 ; A61K31/7072 ; A61K31/513 ; A61K31/706 ; A61K31/7068 ; A61K31/519 ; A61K31/7076 ; A61K31/52 ; A61K31/517 ; A61K31/655 ; A61K31/495 ; A61K31/496 ; A61K31/047 ; A61K31/336 ; A61K31/66 ; A61K31/7028 ; A61K31/155 ; A61K31/396 ; A61K31/10 ; A61K31/4184 ; A61K31/573 ; A61K31/131 ; A61K31/137 ; A61K33/243 ; A61K31/282 ; A61P35/00 ; A61K31/5386 ; A61K31/4439 ; A61K31/4709 ; A61K31/4375 ; A61K31/5383 ; A61K31/444 ; A61K31/501 ; A61K31/5377 ; A61K31/4985 ; A61K31/422 ; A61K31/506 ; A61K31/438 ; A61K31/537 ; A61K31/635 ; A61K31/541 ; A61K47/54 ; C12N5/0783 ; C12N15/62 ; C12N15/86
摘要:
Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.